New Century Financial Group LLC Purchases 134 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

New Century Financial Group LLC increased its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 23.7% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 699 shares of the medical equipment provider’s stock after acquiring an additional 134 shares during the period. New Century Financial Group LLC’s holdings in Intuitive Surgical were worth $343,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of ISRG. Creekmur Asset Management LLC grew its holdings in shares of Intuitive Surgical by 200.0% during the first quarter. Creekmur Asset Management LLC now owns 63 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 42 shares during the last quarter. Ridgewood Investments LLC acquired a new position in Intuitive Surgical during the 2nd quarter worth about $26,000. Delos Wealth Advisors LLC grew its holdings in Intuitive Surgical by 380.0% during the 1st quarter. Delos Wealth Advisors LLC now owns 72 shares of the medical equipment provider’s stock worth $29,000 after acquiring an additional 57 shares during the last quarter. LRI Investments LLC acquired a new stake in Intuitive Surgical in the 1st quarter valued at about $30,000. Finally, LGT Financial Advisors LLC raised its stake in shares of Intuitive Surgical by 415.4% in the second quarter. LGT Financial Advisors LLC now owns 67 shares of the medical equipment provider’s stock worth $30,000 after acquiring an additional 54 shares during the last quarter. 83.64% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Amal M. Johnson sold 2,943 shares of Intuitive Surgical stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $443.30, for a total transaction of $1,304,631.90. Following the transaction, the director now owns 12,275 shares in the company, valued at $5,441,507.50. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Intuitive Surgical news, Director Amy L. Ladd sold 450 shares of the stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $490.28, for a total transaction of $220,626.00. Following the completion of the transaction, the director now owns 821 shares in the company, valued at approximately $402,519.88. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Amal M. Johnson sold 2,943 shares of the business’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $443.30, for a total value of $1,304,631.90. Following the completion of the sale, the director now owns 12,275 shares in the company, valued at approximately $5,441,507.50. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 53,120 shares of company stock worth $25,528,753 over the last ninety days. 0.90% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

ISRG has been the topic of several research analyst reports. Redburn Atlantic raised shares of Intuitive Surgical from a “neutral” rating to a “buy” rating and increased their price target for the company from $380.00 to $510.00 in a research note on Friday, August 2nd. Oppenheimer reissued a “market perform” rating on shares of Intuitive Surgical in a research note on Friday. JPMorgan Chase & Co. boosted their target price on Intuitive Surgical from $495.00 to $575.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. Citigroup raised their price target on Intuitive Surgical from $512.00 to $560.00 and gave the company a “buy” rating in a report on Thursday, August 22nd. Finally, Barclays boosted their price objective on Intuitive Surgical from $430.00 to $490.00 and gave the stock an “overweight” rating in a report on Thursday, July 18th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have issued a buy rating to the company. Based on data from MarketBeat, Intuitive Surgical presently has a consensus rating of “Moderate Buy” and a consensus price target of $513.74.

Intuitive Surgical Stock Performance

ISRG opened at $521.15 on Monday. The firm’s fifty day moving average is $483.85 and its two-hundred day moving average is $438.56. The firm has a market cap of $184.85 billion, a PE ratio of 94.07, a price-to-earnings-growth ratio of 5.40 and a beta of 1.39. Intuitive Surgical, Inc. has a twelve month low of $254.85 and a twelve month high of $523.34.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings data on Thursday, July 18th. The medical equipment provider reported $1.78 EPS for the quarter, topping the consensus estimate of $1.54 by $0.24. The business had revenue of $2.01 billion for the quarter, compared to the consensus estimate of $1.97 billion. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The firm’s revenue was up 14.5% compared to the same quarter last year. During the same quarter last year, the business posted $1.18 EPS. Equities analysts forecast that Intuitive Surgical, Inc. will post 5.22 EPS for the current fiscal year.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.